EMPA-KIDNEY (2023) — Trial Summary

EMPA-KIDNEY (2023): Phase 3 randomized, double-blind, placebo-controlled trial of empagliflozin 10 mg once daily versus placebo in adults with CKD (eGFR 20–<45 mL/min/1.73 m² at any UACR, or eGFR 45–<90 with UACR ≥200 mg/g), with or without diabetes (NCT03594110). Primary composite: kidney disease p

References

NephroResource

Taking longer than expected

If you're on a slow connection or this keeps happening, tap below to reload.